Lisa K. Brents

Assistant Professor

UAMS

Last publication 2024 Last refreshed 2026-05-16

faculty

17 h-index 52 pubs 1,524 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Lisa K. Brents' research investigates substance abuse, maternal and infant health, and animal models of addiction and withdrawal. Her work has explored the impact of environmental factors, such as limited bedding, on ethanol consumption in female rats. She has also examined the pharmacodynamic properties and metabolic resistance of deuterated buprenorphine, as well as its interaction with norbuprenorphine in neonatal opioid withdrawal syndrome. Brents has further investigated the effects of fentanyl in pregnant rats using deuterated buprenorphine. Her publications also include analyses of public responses to FDA inquiries regarding kratom scheduling and the motives for kratom self-medication. Brents has a h-index of 17 and has published 52 papers, accumulating over 1,500 citations. She has a history of collaboration with researchers at the University of Arkansas for Medical Sciences, including Brian J. Parks, Julia Tobacyk, Kyounghyun Kim, and Michael D. Berquist.

Metrics

h-index: 17
Publications: 52
Citations: 1,524

Selected Publications

Deuterated Buprenorphine Mitigates Fentanyl Effects in Pregnant Rats (2024)

DOI OpenAlex
Limited bedding and nesting increases ethanol drinking in female rats (2024)

9 citations DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

2 citations DOI OpenAlex
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)

4 citations DOI OpenAlex
Effects of a two-hit model of early life adversity on oral ethanol self-administration and adrenergic receptor expression in adolescent rats (2023)

DOI OpenAlex
481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

DOI OpenAlex
Response to article – alternative interpretation of “there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome” (2023)

DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. (2022)

DOI OpenAlex
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)

DOI OpenAlex
Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom (2022)

14 citations DOI OpenAlex
Effects of prenatal opioid exposure and early life adversity on opioid‐induced antinociception (2022)

DOI OpenAlex
384 Motives for kratom self-medication: contents of public comments solicited by the FDA (2022)

1 citation DOI OpenAlex
Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software (2021)

14 citations DOI OpenAlex